Goldman Sachs analyst David Roman raised the firm’s price target on Tandem Diabetes (TNDM) to $25 from $16 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care Targets Longer-Wear Infusion Sets in New Home-Use Study
- Tandem Diabetes Care Updates Bylaws, Tightens Governance Rules
- Tandem Diabetes price target raised to $24 from $17 at Truist
- Tandem Diabetes price target raised to $30 from $25 at RBC Capital
- Tandem Diabetes price target raised to $35 from $24 at Canaccord